Scientific and Standardization Committee Communications Comparison of Test Methods for the Lupus Anticoagulant: International Survey on Lupus Anticoagulants-I (ISLA-1)

Summary

Six lyophilized plasma samples were sent to 20 “expert” laboratories for assessment of lupus anticoagulant (LA). Four samples contained pooled LA of graded potency mixed with aged normal plasma. One contained LA plus cephalin phospholipid and one contained a nonspecific venom anticoagulant. Sixteen methods were used overall with some participants using up to 8 methods. Results were scored in regard to the known potencies of LA in the samples and other known induced defects.

Activated partial thromboplastin time (APTT) tests used by most participants for preliminary screening were relatively sensitive, but non-specific. Platelet or phospholipid neutralization procedures (PNP) appeared to be sensitive and specific but showed a non-linear response to increased LA content. Kaolin clotting time (KCT) tests showed the most sensitive response to increased LA content but the weaker LA were not scored as abnormal by most laboratories as the samples may have contained platelet fragments. Other commonly used tests such as the tissue thromboplastin inhibition (TTI) test and the dilute Russell’s viper venom test (DRVVT) were carried out somewhat inconsistently. The variability in performance of tests in different laboratories indicates that standardization of methodology is urgently required.

Generally it seemed that most clotting tests were “bypassed” by the addition of phospholipid to a known LA-positive sample in apparently direct proportion to their sensitivity. Sample preparation, especially prevention of contamination with activated platelets is a vital preliminary part in the assay of LA.

• References

• 1 Lechner K. Lupus anticoagulants and thrombosis. In: Thrombosis and Haemostasis 1987 Verstraete M, Vermylen J, Lijnen HR, Arnout J. (eds). ISTH and Leuven University Press; 1987: 525-547
• 2 Harris EN, Asherson RA, Hughes GR V. Antiphospholipid antibodies - autoantibodies with a difference. Ann Rev Med 1988; 39: 261-271
• 3 Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Progr Haemostas 1972; 1: 75-95
• 4 Green D, Hougie C, Kazmier FJ. et al. Report of the working party on acquired inhibitors of coagulation: Studies of the lupus anticoagulant. Thromb Haemostas 1983; 49: 144-146
• 5 Schleider MA, Nachman RL, Jaffe EA. et al. clinical study of the lupus anticoagulant. Blood 1976; 48: 499-510
• 6 Thiagarajan P, Pengo V, Shapiro S. The use of the dilute Russel Viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869-874
• 7 Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978; 40: 143-151
• 8 Triplett DA, Brandt JT, Kaczor D. et al. Laboratory diagnosis of lupus inhibitors: A comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol 1983; 79: 678-682
• 9 Rosove MH, Ismail M, Koziol BJ. et al. Lupus anticoagulants: Improved diagnosis with a kaolin clotting time using rabbit brain phospholipid in standard and high concentrations. Blood 1986; 68: 472-478
• 10 Harris EN, Gharavi AE, Patel SP. et al. Evaluation of the anti-cardiolipin antibpdy test. Report of an international workshop held April 4, 1986, Clin Exp Immunol 1987 68. 215-222
• 11 AJving BM, Baldwin PE, Richards RL. et al. The dilute phospholipid APTT: A sensitive assay for verification of lupus anticoagulant. Thromb Haemostas 1985; 54: 709-714
• 12 Bird P. Coagulation in an agarose gel and its application to the detection and measurement of factor VIII antibodies. Br J Haematol 1975; 29: 329-340
• 13 Exner T. Comparison of two simple tests for the lupus anticoagulant. American J Clin Pathol 1985; 83: 215-218
• 14 Bell HG, Alton HG. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test. Nature 1954; 174: 880-881
• 15 Exner T, Vaasjoki R. Characterisation and some properties of the protein C activator from Agkistrodon Contortrix venom. Thromb Haemostas 1988; 59: 40-44
• 16 von Felten A. Detection of lupus anticoagulants by the inside out membrane absorption test. Thromb Haemostas 1987 58. 1439 (Abstr).
• 17 Triplett DA. The clinical importance of lupus anticoagulants. The American Society of Clinical Pathologists - Thrombosis and Haemostasis Series 1985; 7 (05) 14
• 18 Exner T, Rickard KA, Kronenberg H. Studies on phospholipids in the action of a lupus coagulation inhibitor. Pathology 1975; 7: 319-328
• 19 Machin SJ, Giddings J, Greaves M. et al. Detection of lupus like anticoagulant: current laboratory practice in the United Kingdom. J Clin Pathol 1990; 43: 73-75
• 20 Firkin BG, Booth R, Hendrix L. et al. Demonstration of a platelet bypass mechanism in the clotting system using an acquired anticoagulant. Am J Haematol 1978; 5: 81-92
• 21 Howard MA, Firkin BG. Investigations of the lupus-like inhibitor bypassing activity of platelets. Thromb Haemostas 1983; 50: 775-777
• 22 Rosner E, Pauzner R, Lusky A. et al. Detection and quantitative evalution of lupus circulating anticoagulant activity. Thromb Haemostas 1987; 57: 144-147
• 23 Lesperance B, David M, Rauch J. et al. Relative sensitivity of different tests in the detection of low titer lupus anticoagulants. Throm Haemostas 1988; 60: 217-219
• 24 Lubbe WF, Butler WS, Palmer ST J. et al. Fetal survival after prednisone suppression of maternal lupus anticoagulant. Lancet 1983; i: 1361-1363
• 25 Gibson J, Starling E, Date L. et al. Simplified screening procedure for detection of the lupus anticoagulant. J Clin Pathol 1988; 41: 226-231
• 26 Gastineau DA, Kazmiere FJ, Nichols WL. et al. Lupus anticoagulant: An analysis of the clinical and laboratory features of 219 cases. Am J Haematol 1985; 19: 265-273
• 27 Triplett DA, Brandt JT, Maas RL. The laboratory heterogeneity of lupus anticoagulants. Arch Pathol Lab Med 1985; 109: 946-951
• 28 Exner T. Similar mechanism of various lupus anticoagulants. Thromb Haemostas 1988; 53: 15-08